These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29168205)

  • 1. A human microdose study of the antimalarial drug GSK3191607 in healthy volunteers.
    Okour M; Derimanov G; Barnett R; Fernandez E; Ferrer S; Gresham S; Hossain M; Gamo FJ; Koh G; Pereira A; Rolfe K; Wong D; Young G; Rami H; Haselden J
    Br J Clin Pharmacol; 2018 Mar; 84(3):482-489. PubMed ID: 29168205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
    Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
    Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a Bayesian hierarchical pharmacokinetic-pharmacodynamic model for predicting parasitological outcomes in Phase 2 studies of new antimalarial drugs.
    Tully MK; Dini S; Flegg JA; McCarthy JS; Price DJ; Simpson JA
    Antimicrob Agents Chemother; 2024 Sep; 68(9):e0086324. PubMed ID: 39136464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A.
    Ostenfeld T; Beaumont C; Bullman J; Beaumont M; Jeffrey P
    Br J Clin Pharmacol; 2012 Dec; 74(6):1033-44. PubMed ID: 22497298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.
    McCarthy JS; Rückle T; Djeriou E; Cantalloube C; Ter-Minassian D; Baker M; O'Rourke P; Griffin P; Marquart L; Hooft van Huijsduijnen R; Möhrle JJ
    Malar J; 2016 Sep; 15(1):469. PubMed ID: 27624471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion-451840 in an induced blood stage malaria study in healthy subjects.
    Krause A; Dingemanse J; Mathis A; Marquart L; Möhrle JJ; McCarthy JS
    Br J Clin Pharmacol; 2016 Aug; 82(2):412-21. PubMed ID: 27062080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.
    Phyo AP; Jittamala P; Nosten FH; Pukrittayakamee S; Imwong M; White NJ; Duparc S; Macintyre F; Baker M; Möhrle JJ
    Lancet Infect Dis; 2016 Jan; 16(1):61-69. PubMed ID: 26448141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.
    Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Brian Houston J; Oosterhuis B; Bjerrum OJ; Grynkiewicz G; Alder J; Rowland M; Garner C
    Eur J Pharm Sci; 2011 Jun; 43(3):141-50. PubMed ID: 21540108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hollow-Fiber Methodology for Pharmacokinetic/Pharmacodynamic Studies of Antimalarial Compounds.
    Caton E; Nenortas E; Bakshi RP; Shapiro TA
    Curr Protoc Chem Biol; 2016 Mar; 8(1):29-58. PubMed ID: 26995353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers.
    McCarthy JS; Baker M; O'Rourke P; Marquart L; Griffin P; Hooft van Huijsduijnen R; Möhrle JJ
    J Antimicrob Chemother; 2016 Sep; 71(9):2620-7. PubMed ID: 27272721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development.
    McCarthy JS; Marquart L; Sekuloski S; Trenholme K; Elliott S; Griffin P; Rockett R; O'Rourke P; Sloots T; Angulo-Barturen I; Ferrer S; Jiménez-Díaz MB; Martínez MS; Hooft van Huijsduijnen R; Duparc S; Leroy D; Wells TN; Baker M; Möhrle JJ
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3669-75. PubMed ID: 27044554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients.
    Park WS; Park GJ; Han S; Ban S; Park MY; Kim SH; Kim SM; Kim YC; Kim HS; Shin YG; Yim DS
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):363-369. PubMed ID: 28660432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model.
    Deye GA; Miller RS; Miller L; Salas CJ; Tosh D; Macareo L; Smith BL; Fracisco S; Clemens EG; Murphy J; Sousa JC; Dumler JS; Magill AJ
    Clin Infect Dis; 2012 Jan; 54(2):232-9. PubMed ID: 22052893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the Stable Isotope Label Approach in Clinical Development-Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life Compound.
    Goyal N; Mohamed K; Rolfe K; Sahota S; Ernest T; Duparc S; Taylor M; Casillas L; Koh GCKW
    AAPS J; 2018 Jun; 20(4):74. PubMed ID: 29869298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.
    Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Houston B; Oosterhuis B; Bjerrum OJ; Rowland M; Garner C
    Eur J Pharm Sci; 2010 May; 40(2):125-31. PubMed ID: 20307657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria.
    Ruangweerayut R; Looareesuwan S; Hutchinson D; Chauemung A; Banmairuroi V; Na-Bangchang K
    Malar J; 2008 Oct; 7():225. PubMed ID: 18973702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.
    Garner CR; Park KB; French NS; Earnshaw C; Schipani A; Selby AM; Byrne L; Siner S; Crawley FP; Vaes WH; van Duijn E; deLigt R; Varendi H; Lass J; Grynkiewicz G; Maruszak W; Turner MA
    Br J Clin Pharmacol; 2015 Jul; 80(1):157-67. PubMed ID: 25619398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
    Zhang YK; Plattner JJ; Easom EE; Jacobs RT; Guo D; Freund YR; Berry P; Ciaravino V; Erve JCL; Rosenthal PJ; Campo B; Gamo FJ; Sanz LM; Cao J
    J Med Chem; 2017 Jul; 60(13):5889-5908. PubMed ID: 28635296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects.
    Madan A; O'Brien Z; Wen J; O'Brien C; Farber RH; Beaton G; Crowe P; Oosterhuis B; Garner RC; Lappin G; Bozigian HP
    Br J Clin Pharmacol; 2009 Mar; 67(3):288-98. PubMed ID: 19523012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimalarial pharmacodynamics and pharmacokinetics of a third-generation antifolate--JPC2056--in cynomolgus monkeys using an in vivo in vitro model.
    Edstein MD; Kotecka BM; Ager AL; Smith KS; DiTusa CA; Diaz DS; Kyle DE; Schiehser GA; Jacobus DP; Rieckmann KH; O'Neil MT
    J Antimicrob Chemother; 2007 Oct; 60(4):811-8. PubMed ID: 17646199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.